(Reuters) - Denmark’s Novo Nordisk, the world’s biggest maker of insulin, has received a U.S. subpoena requesting documents relating to potential manufacturing issues at its Kalundborg plant in Denmark, the company said on Friday.
The Kalundborg factory 100 km west of Copenhagen is the world’s biggest insulin production site, making half the world’s supply. It also produces another kind of non-insulin diabetes treatment known as GLP-1 medicine.
The company said the request came from the office of the U.S. Attorney for the District of Massachusetts, adding that it related to “certain production units”.
Help employers find you! Check out all the jobs and post your resume.